Aim: The purpose of this study was to assess whether pantoprazole could be a new treatment option in the therapy of children with obesity and insulin resistance.
Methods: This study was conducted on 46 children and adolescents with exogenous obesity and insulin resistance. The patients were randomly chosen and divided into therapeutic groups of metformin, pantoprazole, and metformin plus pantoprazole.
Results: There was no difference between the groups in terms of age, gender, and anthropometric measurements made before therapy. In the pre-therapy OGTT, the glucose levels at 60 and 90 min were highest in the metformin group and lowest in the pantoprazole group. In the post-therapy OGTT, the glucose level at 60 and 90 min were lowest in the metformin group which had the highest level prior to therapy. Likewise, the metformin group showed the lowest insulin levels at 60, 90, and 120 min. When the post-therapy values of HOMA-IR, Quick index, and fasting insulin:glucose ratio were compared, there was a significant improvement in all three groups, however, when the groups were compared with each other, there was no statistically significant difference between the groups in terms of improvement.
Conclusion: Pantoprazole may be a new treatment option for children and adolescents with obesity and insulin resistance.
01 - 03 Oct 2015
European Society for Paediatric Endocrinology